Overview of Cell Signaling Pathways in Cancer

  • Amanda J. HarveyEmail author


There are many different signaling pathways that contribute to development and cellular homeostasis. In diseases, especially cancer, development components of these pathways often become mutated or overexpressed causing dysregulation of cellular signaling. This chapter provides an overview of the key pathways involved in tumor development and progression and studies some of the complications associated with therapeutic targeting, namely, signaling cross talk and biomarker identification.


EGFR Cancer Cell signaling Biomarkers Therapeutic targets MAPK 


  1. 1.
    Hanahan D, Wienberg RA. Hallmarks of cancer: the next generation. Cell. 2011;144(5):646–74.CrossRefGoogle Scholar
  2. 2.
    Cruickshanks N, Zhang Y, Yuan F, Pahuski M, Gibert M, Abdounder R. Role and therapeutic targeting of the HGF/MET pathway in glioblastoma. Cancer. 2017;9:87–102.CrossRefGoogle Scholar
  3. 3.
    Westermark B. Platelet-derived growth factor in glioblastoma—driver or biomarker? Ups J Med Sci. 2014;119:298–305.CrossRefPubMedPubMedCentralGoogle Scholar
  4. 4.
    Slebioda TJ, Kmiec Z. Tumour necrosis factor superfamily members in the pathogenesis of inflammatory bowel disease. Mediat Inflamm. 2014;2014:325129.CrossRefGoogle Scholar
  5. 5.
    Keppler-Noreuil KM, Parker VER, Darling TN, Martinez-Agosoto JA. Somatic growth disorders of the PI3K/AKT/mTOR pathways and therapeutic strategies. Am J Med Genet. 2016;172C:402–21.CrossRefGoogle Scholar
  6. 6.
    Hare SH, Harvey AJ. mTOR function and therapeutic targeting in breast cancer. Am J Cancer Res. 2017;7(3):383–404.PubMedPubMedCentralGoogle Scholar
  7. 7.
    Cristea S, Sage J. Is the canonical RAF/MEK/ERK signaling oath way a therapeutic target in SCLC. J Thorac Oncol. 2016;11(8):1233–41.CrossRefPubMedPubMedCentralGoogle Scholar
  8. 8.
    McCubrey JA, Rakus D, Gizak A, Steelman LS, Abrams SL, Lertpiriyapong K, et al. Effects of mutations in the Wnt/β-catenin, hedgehog, notch and PI3K pathways on GsK-3 activity – diverse effects on cell growth, metabolism and cancer. Biochim Biophys Acta. 2016;1863:2942–76.CrossRefPubMedGoogle Scholar
  9. 9.
    Bosman MCJ, Schuringa JJ, Vellenga E. Constitutive NK-κB activation in AML: causes and treatment strategies. Crit Rev Oncol. 2016;98:35–44.CrossRefGoogle Scholar
  10. 10.
    Choudary I, Barr PM, Friedberg J. Recent advances in the development of Aurora kinases inhibitors in hematological malignancies. Ther Adv Hematol. 2015;6(6):282–94.CrossRefPubMedPubMedCentralGoogle Scholar
  11. 11.
    Harvey AJ. Signalling cross talk. In: Harvey AJ, editor. Cancer cell signalling. Chichester: Wiley Blackwell; 2013. p. 193–206.Google Scholar
  12. 12.
    Montemurro F, Scaltriti M. Biomarkers of rugs targeting HER-family signaling in cancer. J Pathol. 2014;232:219–29.CrossRefPubMedGoogle Scholar
  13. 13.
    Augustine TA, Baig M, Sood A, Budagov T, Atzmon G, Mariadason JM, Aparo S, Maitra R, Goel S. Telomere length is a novel predictive biomarker of sensitivity to anti-EGFR therapy in metastatic colorectal cancer. Br J Cancer. 2015;112:313–8.CrossRefPubMedGoogle Scholar
  14. 14.
    Yang J, Li S, Wang B, Wu Y, Chen Z, Lv M, et al. Potential biomarkers for anti-EGFR therapy in metastatic colorectal cancer. Tumour Biol. 2016;37:11645–55.CrossRefPubMedGoogle Scholar
  15. 15.
    Hussain HA, Harvey AJ. Evolution of breast cancer therapeutics: breast tumour kinase’s role in breast cancer and hope for breast tumour kinase targeted therapy. World J Clin Oncol. 2014;5(3):299–310.CrossRefPubMedPubMedCentralGoogle Scholar
  16. 16.
    Martin M, Wei H, Tao L. Targeting the microenvironment in cancer therapeutics. Oncotarget. 2016;7(32):52272–583.CrossRefGoogle Scholar

Copyright information

© Springer Nature Switzerland AG 2019

Authors and Affiliations

  1. 1.Department of Life SciencesBrunel University LondonUxbridgeUK

Personalised recommendations